A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.
Latest Information Update: 31 Jul 2026
At a glance
- Drugs Iparomlimab (Primary) ; Iparomlimab/tuvonralimab (Primary)
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 02 Jun 2026 An interim analysis is planned as per trial design presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2026 Trial design presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2026 Status changed from not yet recruiting to recruiting as per trial design presented at the 62nd Annual Meeting of the American Society of Clinical Oncology